Shares of Therapix Biosciences Ltd. gained 24 percent Monday on top-line results from a phase IIa study showing that THX-110 significantly improved symptoms over time in adults with Tourette syndrome. The Tel Aviv, Israel-based firm plans to launch a larger, randomized, double-blind trial to test the cannabinoid product, which combines dronabinol and palmitoylethanolamide.